Data from the TRIBUTE trial (chemotherapy with or without erlotinib for previously untreated patients with NSCLC) suggest that, in KRAS mutated patients, OS and RR may be worse with the addition of EGFR TKI [81]. Here, KRAS is linked to non-small cell lung carcinoma.